8-K
filed April 4, 2024, 7:59 PM ET
ticker TRAW
CIK 0001130598
M&A
confidence high
sentiment neutral
materiality 1.00
Traws Pharma, Inc. (TRAW): M&A transaction — Onconova merges with Trawsfynydd, changes name to Traws Pharma, raises $14M PIPE
Traws Pharma, Inc.
- Acquired Trawsfynydd in reverse merger; issued 3,549,538 common shares and 10,359 Series C preferred shares to Trawsfynydd stockholders.
- Company renamed Traws Pharma, Inc.; ticker changed to TRAW on Nasdaq.
- New leadership: Werner Cautreels appointed CEO; Iain Dukes Executive Chairman; Nikolay Savchuk COO; Robert Redfield CMO; C. David Pauza CSO Virology.
- Concurrent $14M PIPE financing: sold 496,935 common shares and 1,578 Series C preferred shares to Torrey Pines affiliate and OrbiMed.
- CVRs issued to all common shareholders as of April 15, 2024, entitling to 43.7% of net proceeds from sale of rigosertib/narazaciclib or 6.24% of net sales.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
C. David Pauza was appointed as Chief Scientific Officer, Virology at Traws Pharma, Inc..
- Action
- appointed
- Role
- Chief Scientific Officer, Virology
Exact text from the filing
In addition, effective immediately upon the Closing, C. David Pauza was appointed the Company’s Chief Scientific Officer, Virology and Robert Redfield was appointed the Company’s Chief Medical Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nikolay Savchuk was appointed as Chief Operating Officer at Traws Pharma, Inc..
- Action
- appointed
- Role
- Chief Operating Officer
Exact text from the filing
appointed Werner Cautreels as the Company’s CEO and Nikolay Savchuk as the Company’s COO
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Iain Dukes was appointed as Executive Chairman at Traws Pharma, Inc..
- Action
- appointed
- Role
- Executive Chairman
Exact text from the filing
appointed Iain Dukes as a director and Executive Chairman of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Atadja resigned as Director at Traws Pharma, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Viren Mehta resigned as Director at Traws Pharma, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Werner Cautreels was appointed as Chief Executive Officer at Traws Pharma, Inc..
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
appointed Werner Cautreels as the Company’s CEO and Nikolay Savchuk as the Company’s COO
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mark Guerin departed as Chief Financial Officer at Traws Pharma, Inc..
- Action
- resigned as COO and remained as CFO
- Role
- Chief Financial Officer
Exact text from the filing
Mark Guerin remained as the Chief Financial Officer of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Steven M. Fruchtman resigned as Director at Traws Pharma, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Redfield was appointed as Chief Medical Officer at Traws Pharma, Inc..
- Action
- appointed
- Role
- Chief Medical Officer
Exact text from the filing
In addition, effective immediately upon the Closing, C. David Pauza was appointed the Company’s Chief Scientific Officer, Virology and Robert Redfield was appointed the Company’s Chief Medical Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jerome Groopman resigned as Director at Traws Pharma, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Steven M. Fruchtman was appointed as President and Chief Scientific Officer, Oncology at Traws Pharma, Inc..
- Action
- remained as the President of the Company and was appointed Chief Scientific Officer, Oncology
- Role
- President and Chief Scientific Officer, Oncology
Exact text from the filing
Dr. Steven M. Fruchtman remained as the President of the Company and was appointed Chief Scientific Officer, Oncology
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Traws Pharma, Inc.: Filed Certificate of Designation for Series C Non-Voting Convertible Preferred Stock on April 1, 2024 (effective 2024-04-01).
- Change
- charter amendment
- Effective
- 2024-04-01
Exact text from the filing
On April 1, 2024, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Merger referenced in Item 1.01 above.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Traws Pharma, Inc.: Changed company name to Traws Pharma, Inc. via certificate of amendment to Tenth Amended and Restated Certificate of Incorporation on April 2, 2024 (effective 2024-04-02).
- Change
- charter amendment
- Effective
- 2024-04-02
Exact text from the filing
On April 2, 2024, the Company changed its name to Traws Pharma, Inc. pursuant to a certificate of amendment to its Tenth Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware (the “Name Change”).
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.99
Traws Pharma, Inc. completed an acquisition involving Trawsfynydd Therapeutics, Inc. for 3,549,538 shares of common stock and 10,359.0916 shares of Series C Preferred Stock (closed 2024-04-01).
- Action
- acquisition
- Counterparty
- Trawsfynydd Therapeutics, Inc.
- Consideration
- 3,549,538 shares of common stock and 10,359.0916 shares of Series C Preferred Stock
- Closing
- 2024-04-01
Exact text from the filing
shares of capital stock of Trawsfynydd immediately prior to the effective time of the First Merger, the Company issued to the stockholders of Trawsfynydd an aggregate of (A) 3,549,538 shares of common stock of the Company, par value $0.01 per share (the “Common Stock”) and (B) 10,359.0916 shares of Series C Preferred Stock (as defined and described below). Each
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.